Bristol Myers Squibb (CELG-RI) Research & Development (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Research & Development of $3.0 billion for Q2 2026, up 14.69% year-over-year from $2.6 billion in Q2 2025, and up 11.7% quarter-over-quarter from $2.6 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Research & Development (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Research & Development for 18 consecutive years, with $3.0 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Research & Development rose 14.69% year-over-year to $3.0 billion; the TTM figure through Jun 2026 stood at $10.7 billion (up 3.08% YoY), while the FY2025 annual figure was $10.0 billion, down 10.83% from the prior year.
- Research & Development advanced to $3.0 billion in Q2 2026 per CELG-RI's latest filing, from $2.6 billion in the prior quarter.
- Across five years, Research & Development topped out at $3.2 billion in Q4 2024 and bottomed at $2.2 billion in Q3 2023.
- Historically, Research & Development has averaged $2.5 billion across 5 years, with a median of $2.5 billion in 2022.
- Annual changes were most pronounced in 2024 — Research & Development advanced 28.77% — and 2025, when it retreated 18.96%.
- Bristol Myers Squibb's Research & Development stood at $2.5 billion in 2022, then declined by 1.27% to $2.5 billion in 2023, then rose by 28.77% to $3.2 billion in 2024, then declined by 18.96% to $2.6 billion in 2025, then grew by 14.42% to $3.0 billion in 2026.
- Business Quant data shows CELG-RI's Research & Development at $3.0 billion in Q2 2026, $2.6 billion in Q1 2026, and $2.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 2.85 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 4.05 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -4.65 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 2.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.96 Bn |
| Mar 31, 2026 | 2.65 Bn |
| Dec 31, 2025 | 2.59 Bn |
| Sep 30, 2025 | 2.53 Bn |
| Jun 30, 2025 | 2.58 Bn |
| Mar 31, 2025 | 2.26 Bn |
| Dec 31, 2024 | 3.19 Bn |
| Sep 30, 2024 | 2.37 Bn |
| Jun 30, 2024 | 2.90 Bn |
| Mar 31, 2024 | 2.70 Bn |
| Dec 31, 2023 | 2.48 Bn |
| Sep 30, 2023 | 2.24 Bn |
| Jun 30, 2023 | 2.26 Bn |
| Mar 31, 2023 | 2.32 Bn |
| Dec 31, 2022 | 2.51 Bn |
| Sep 30, 2022 | 2.42 Bn |
| Jun 30, 2022 | 2.32 Bn |
| Mar 31, 2022 | 2.26 Bn |
| Dec 31, 2021 | 2.52 Bn |
| Sep 30, 2021 | 2.98 Bn |